{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:02:25Z","timestamp":1789794145289,"version":"4.0.1"},"reference-count":63,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/bst.2026.01217","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:11:11Z","timestamp":1787868671000},"page":"373-384","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic arterial infusion chemotherapy\u2013based triplet conversion therapy for hepatocellular carcinoma with portal vein tumor thrombus: Evidence, patient selection, and surgical endpoints"],"prefix":"10.5582","volume":"20","author":[{"given":"Chaosheng","family":"Xia","sequence":"first","affiliation":[{"name":"Second Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"He","sequence":"first","affiliation":[{"name":"Second Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfu","family":"Hong","sequence":"additional","affiliation":[{"name":"Second Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenda","family":"Wang","sequence":"additional","affiliation":[{"name":"Second Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyu","family":"Li","sequence":"additional","affiliation":[{"name":"Second Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Second Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitian","family":"Shi","sequence":"additional","affiliation":[{"name":"Second Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74:229-263.","DOI":"10.3322\/caac.21834"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7:6.","DOI":"10.1038\/s41572-020-00240-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Reig M, Sanduzzi-Zamparelli M, Forner A, <i>et al<\/i>. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. J Hepatol. 2026; 84:631-654.","DOI":"10.1016\/j.jhep.2025.10.020"},{"key":"4","unstructured":"4. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025; 82:315-374."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Singal AG, Llovet JM, Yarchoan M, <i>et al<\/i>. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78:1922-1965.","DOI":"10.1097\/HEP.0000000000000466"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Vogel A, Chan SL, Dawson LA, Kelley RK, Llovet JM, Meyer T, Ricke J, Rimassa L, Sapisochin G, Vilgrain V, Zucman-Rossi J, Ducreux M, ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025; 36:491-506.","DOI":"10.1016\/j.annonc.2025.02.006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gordan JD, Kennedy EB, Abou-Alfa GK, <i>et al<\/i>. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024; 42:1830-1850.","DOI":"10.1200\/JCO.23.02745"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lau G, Obi S, Zhou J, <i>et al<\/i>. APASL clinical practice guidelines on systemic therapy for hepatocellularcarcinoma-2024. Hepatol Int. 2024; 18:1661-1683.","DOI":"10.1007\/s12072-024-10732-z"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022; 28:583-705.","DOI":"10.3350\/cmh.2022.0294"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hasegawa K, Takemura N, Yamashita T, <i>et al<\/i>. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC guidelines). Hepatol Res. 2023; 53:383-390.","DOI":"10.1111\/hepr.13892"},{"key":"11","unstructured":"11. Chinese Association of Liver Cancer and Chinese Medical Doctor Association. Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2026 edition) (in Chinese). Zhonghua Yi Xue Za Zhi. 2026; 106:41-55."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N, Liver Cancer Study Group of Japan. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016; 65:938-943.","DOI":"10.1016\/j.jhep.2016.05.044"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 edition). Liver Cancer. 2020; 9:28-40.","DOI":"10.1159\/000503685"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Finn RS, Qin S, Ikeda M, <i>et al<\/i>. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382:1894-1905.","DOI":"10.1056\/NEJMoa1915745"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Finn RS, Galle PR, Ducreux M, Cheng AL, Reilly N, Nicholas A, Hernandez S, Ma N, Merle P, Salem R, Li D, Breder V. Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in IMbrave150. Liver Cancer. 2024; 13:655-668.","DOI":"10.1159\/000539897"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Abou-Alfa GK, Lau G, Kudo M, <i>et al<\/i>. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022; 1:EVIDoa2100070.","DOI":"10.1056\/EVIDoa2100070"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Qin S, Chan SL, Gu S, <i>et al<\/i>. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): A randomised, open-label, international phase 3 study. Lancet. 2023; 402:1133-1146.","DOI":"10.1016\/S0140-6736(23)00961-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ren Z, Xu J, Bai Y, <i>et al<\/i>. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study. Lancet Oncol. 2021; 22:977-990.","DOI":"10.1016\/S1470-2045(21)00252-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yau T, Galle PR, Decaens T, <i>et al<\/i>. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): An open-label, randomised, phase 3 trial. Lancet. 2025; 405:1851-1864.","DOI":"10.1016\/S0140-6736(25)00403-9"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Qin S, Gu S, Chan SL, <i>et al<\/i>. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): Final analysis of a randomised, open-label, international, phase 3 study. Lancet Oncol. 2025; 26:1598-1611.","DOI":"10.1016\/S1470-2045(25)00543-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Llovet JM, Kudo M, Merle P, <i>et al<\/i>. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): A randomised, double-blind, phase 3 trial. Lancet Oncol. 2023; 24:1399-1410.","DOI":"10.1016\/S1470-2045(23)00469-2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. He M, Li Q, Zou R, <i>et al<\/i>. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial. JAMA Oncol. 2019; 5:953-960.","DOI":"10.1001\/jamaoncol.2019.0250"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Zheng K, Zhu X, Fu S, <i>et al<\/i>. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: A randomized trial. Radiology. 2022; 303:455-464.","DOI":"10.1148\/radiol.211545"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol. 2022; 40:468-480.","DOI":"10.1200\/JCO.21.01963"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A randomized phase III trial. J Clin Oncol. 2022; 40:150-160.","DOI":"10.1200\/JCO.21.00608"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Galluzzi L, Vitale I, Warren S, <i>et al<\/i>. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020; 8:e000337.","DOI":"10.1136\/jitc-2019-000337corr1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol. 2018; 15:325-340.","DOI":"10.1038\/nrclinonc.2018.29"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Shigeta K, Datta M, Hato T, <i>et al<\/i>. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology. 2020; 71:1247-1261.","DOI":"10.1002\/hep.30889"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Zhou KQ, Zhong YC, Song MF, Sun YF, Zhu W, Cheng JW, Xu Y, Zhang ZF, Wang PX, Tang Z, Zhou J, Zhang LY, Fan J, Yang XR. Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution. Hepatology. 2025; 82:566-581.","DOI":"10.1097\/HEP.0000000000001182"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Tong W, Zhong J, Yang Q, Lin H, Chen B, Lu T, Chen J, Luo N. Single-cell and bulk transcriptomic datasets enable the development of prognostic models based on dynamic changes in the tumor immune microenvironment in patients with hepatocellular carcinoma and portal vein tumor thrombus. Front Immunol. 2024; 15:1414121.","DOI":"10.3389\/fimmu.2024.1414121"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D, Li Q, Xu L, Zhang Y, Wei W, Chen M, Kan A, Shi M. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. Eur J Cancer. 2022; 174:68-77.","DOI":"10.1016\/j.ejca.2022.07.005"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Zhang TQ, Geng ZJ, Zuo MX, Li JB, Huang JH, Huang ZL, Wu PH, Gu YK. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): A phase II study. Signal Transduct Target Ther. 2023; 8:413.","DOI":"10.1038\/s41392-023-01663-6"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Zang M, Li Q, Hu X, Pang H, Li R, Li W, Chen Y, Zhu P, Su K, Yuan G, Li Y, Li Y, Chen J. Camrelizumab combined with lenvatinib and RALOX-hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma (Cal Era): A prospective, single-arm, phase II trial. Liver Cancer. 2025; 14:731-742.","DOI":"10.1159\/000546575"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Shen L, Cao F, Liu Y, Nuerhashi G, Lin L, Tan H, Wen C, Wang Y, Chen S, Zou H, Xie L, Fan W. Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): A phase II trial. BMC Med. 2025; 23:275.","DOI":"10.1186\/s12916-025-04110-1"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Li Y, Guo J, Liu W, Pang H, Song Y, Wu S, Zhang F, Yan D, Chen J, An C, Li C. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: A multicenter propensity score-matching analysis. Hepatol Int. 2024; 18:1286-1298.","DOI":"10.1007\/s12072-024-10672-8"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Zuo M, Zheng G, Cao Y, Lu H, Li D, An C, Fan W. Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high risk: A propensity score matching study. Int J Surg. 2025; 111:104-112.","DOI":"10.1097\/JS9.0000000000001940"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Tang S, Shi F, Xiao Y, Cai H, Ma P, Zhou Y, Wu Z, Chen S, Guo W. HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion. Hepatol Int. 2025; 19:106-117.","DOI":"10.1007\/s12072-024-10762-7"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Wang X, Chen S, Yu W, Liu W, Fang Z. A retrospective study of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and PD-1 inhibitors in hepatocellular carcinoma patients with main portal vein tumor thrombus (Vp4). J Hepatocell Carcinoma. 2026; 13:562766.","DOI":"10.2147\/JHC.S562766"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Liu W, Zhang K, Chen S, Wang X, Yu W. Hepatic arterial infusion chemotherapy plus tyrosine kinase inhibitors with or without PD-1 inhibitors for advanced hepatocellular carcinoma with Vp4 portal vein tumor thrombosis: A retrospective cohort study. Front Immunol. 2026; 17:1832313.","DOI":"10.3389\/fimmu.2026.1832313"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Yuan Y, He W, Yang Z, Qiu J, Huang Z, Shi Y, Lin Z, Zheng Y, Chen M, Lau WY, Li B, Yuan Y. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: A propensity score matching study. Int J Surg. 2023; 109:1222-1230.","DOI":"10.1097\/JS9.0000000000000256"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Guan R, Zhang N, Deng M, Lin Y, Huang G, Fu Y, Zheng Z, Wei W, Zhong C, Zhao H, Mei J, Guo R. Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors. Int J Surg. 2024; 110:4062-4073.","DOI":"10.1097\/JS9.0000000000001378"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Luo L, Xiao Y, Zhu G, Huang A, Song S, Wang T, Ge X, Xie J, Deng W, Hu Z, Wen W, Mei H, Wan R, Shan R. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience. Front Oncol. 2022; 12:1004652.","DOI":"10.3389\/fonc.2022.1004652"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, Liu P, Xu HF, Gao QZ, Yang RJ. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy. 2021; 13:1395-1405.","DOI":"10.2217\/imt-2021-0192"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Yalikun K, Li Z, Zhang J, <i>et al<\/i>. Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: A single-arm exploratory trial. BMC Cancer. 2025; 25:838.","DOI":"10.1186\/s12885-025-14250-5"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Liu J, Zhang S, Shao H. Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): Study protocol of a multicentre, retrospective, target trial emulation design. BMJ Open. 2025; 15:e099510.","DOI":"10.1136\/bmjopen-2025-099510"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Wang J, Hu Y, Zhou L, Yang Y, Chen J, Chen H, Wang H. Non-surgery strategy versus hepatectomy in hepatocellular carcinoma patients with complete response after conversion therapy: A meta-analysis. World J Surg Oncol. 2024; 22:349.","DOI":"10.1186\/s12957-024-03645-6"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022; 76:959-974.","DOI":"10.1007\/978-3-031-08552-9"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Han T, Chen L, Liu N, <i>et al<\/i>. Repurposed acarbose targets nidogen-1 to remodel the tumor stroma and suppress portal vein tumor thrombus in hepatocellular carcinoma. Research (Wash D C). 2026; 9:1161.","DOI":"10.34133\/research.1161"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, Hershman DL, Loehrer AP, Sabichi AL, Symington BE, Terrault N, Wong ML, Somerfield MR, Artz AS. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020; 38:3698-3715.","DOI":"10.1200\/JCO.20.01757"},{"key":"50","unstructured":"50. ClinicalTrials.gov. Combination therapy of HAIC and HLX10 and HLX04 in HCC with major portal vein tumor thrombosis (NCT04947826). <i>https:\/\/clinicaltrials.gov\/study\/NCT04947826<\/i> (accessed August 13, 2026)."},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, Lee HC, Lim YS. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: A randomized clinical trial. JAMA Oncol. 2018; 4:661-669.","DOI":"10.1001\/jamaoncol.2017.5847"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Dawson LA, Winter KA, Knox JJ, <i>et al<\/i>. Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: The NRG Oncology\/RTOG 1112 phase 3 randomized clinical trial. JAMA Oncol. 2025; 11:136-144.","DOI":"10.1001\/jamaoncol.2024.5403"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Silva JP, Berger NG, Tsai S, Christians KK, Clarke CN, Mogal H, White S, Rilling W, Gamblin TC. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: A systematic review and meta-analysis. HPB (Oxford). 2017; 19:659-666.","DOI":"10.1016\/j.hpb.2017.04.016"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Kim PH, Choi SH, Kim JH, Park SH. Comparison of radioembolization and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis: A systematic review and meta-analysis of safety and efficacy. Korean J Radiol. 2019; 20:385-398.","DOI":"10.3348\/kjr.2018.0496"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Vilgrain V, Pereira H, Assenat E, <i>et al<\/i>. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial. Lancet Oncol. 2017; 18:1624-1636.","DOI":"10.1016\/S1470-2045(17)30683-6"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Chow PKH, Gandhi M, Tan SB, <i>et al<\/i>. SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018; 36:1913-1921.","DOI":"10.1200\/JCO.2017.76.0892"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Liu B, Grindrod N, Meyers BM, Freiburger S, Boldt G, Malik A, Jairam MP, Brahmania M, Cardarelli Leite L, Simone CB 2nd, Chow R, Lock M. Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: A systematic review and meta-analysis. Ann Palliat Med. 2023; 12:1165-1174.","DOI":"10.21037\/apm-23-463"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Leung JH, Wang SY, Leung HWC, Chan ALF. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: Patient-level network meta-analysis. Front Oncol. 2024; 14:1344798.","DOI":"10.3389\/fonc.2024.1344798"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Eisenhauer EA, Therasse P, Bogaerts J, <i>et al<\/i>. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-247.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30:52-60.","DOI":"10.1055\/s-0030-1247132"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Johnson PJ, Berhane S, Kagebayashi C, <i>et al<\/i>. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33:550-558.","DOI":"10.1200\/JCO.2014.57.9151"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016; 183:758-764.","DOI":"10.1093\/aje\/kwv254"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016; 79:70-75.","DOI":"10.1016\/j.jclinepi.2016.04.014"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/4\/20_2026.01217\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:29:37Z","timestamp":1789792177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/4\/20_2026.01217\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2026.01217","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01217"}}